Shelter Pharma Ltd Launches New Folic Acid Tablet in International Market
Shelter Pharma Ltd has announced the launch of a new healthcare product, FOLIMAN FOLIC ACID TABLETS (Vitamin B-9 Supplement). The launch, set for May 11, 2026, is designed to enhance the company's portfolio and support its strategic growth in the healthcare and nutraceutical segments.The introduction of the Folic Acid Tablet falls under the category of pharmaceutical and nutraceutical products, marking a key step in Shelter Pharma Ltd's business expansion efforts.
The company specified that the product is being launched in the international market, though it may subsequently introduce the same product in the domestic market in due course.
Key details regarding the new product launch are as follows:
| Particulars | Details |
|---|---|
| Product Name | FOLIMAN FOLIC ACID TABLETS |
| Product Type | Folic Acid Tablet (Vitamin B-9 Supplement) |
| Category | Healthcare / Nutraceutical / Pharmaceutical Product |
| Launch Date | May 11, 2026 |
| Target Market | International (Potential subsequent domestic launch) |
Shelter Pharma Ltd stated that the launch of this new product is expected to strengthen the company's presence within the healthcare segment and contribute positively to future business growth. The move aligns with the company's commitment to introducing quality healthcare products and generating sustainable value for its stakeholders.
The company's Managing Director, Mustaqim Nisarahmed Sabugar, oversaw the announcement of the product line enhancement.
Stock Price Movement
As of 11:05, Shelter Pharma Ltd is ticking up strongly at ₹32.39, having gained 7.93% in the trading session. Shares have traded through a wide intraday range, moving between a low of ₹31.79 and a high of ₹32.40.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.